Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kulmatycki, Kenneth
31  Ergebnisse:
Personensuche X
?
1

WCN24-750 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN:

Schmouder, Robert ; Kulmatycki, Kenneth ; Shah, Bharti..
Kidney International Reports.  9 (2024)  4 - p. S112-S113 , 2024
Link: https://doi.org/10.1016/..
 
?
2

WCN24-748 ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON..:

Schmouder, Robert ; Kulmatycki, Kenneth ; Getz, Elise Burmeister..
Kidney International Reports.  9 (2024)  4 - p. S112 , 2024
Link: https://doi.org/10.1016/..
 
?
3

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN:

Schmouder, Robert ; Junge, Guido ; Nidamarthy, Prasanna Kumar.
Kidney International Reports.  9 (2024)  4 - p. S111-S112 , 2024
Link: https://doi.org/10.1016/..
 
?
4

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCRE..:

Schmouder, Robert ; Junge, Guido ; Milojevic, Julie..
Kidney International Reports.  9 (2024)  4 - p. S111 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Efficacy and Safety of Iptacopan in Patients With C3 Glomer..:

Wong, Edwin ; Nester, Carla ; Cavero, Teresa...
Kidney International Reports.  8 (2023)  12 - p. 2754-2764 , 2023
Link: https://doi.org/10.1016/..
 
?
6

#4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINET..:

Schmouder, Robert ; Lestini, Giulia ; Bartels, Christian...
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
7

#3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSI..:

Schmouder, Robert ; Junge, Guido ; Nidamarthy, Prasanna.
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
8

#4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOK..:

Schmouder, Robert ; Junge, Guido ; Nidamarthy, Prasanna.
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
9

Translational Population‐Pharmacodynamic Modeling of a Nove..:

Gosselin, Nathalie H. ; Schuck, Virna J. A. ; Barriere, Olivier...
Clinical Pharmacology & Therapeutics.  113 (2022)  2 - p. 328-338 , 2022
Link: https://doi.org/10.1002/..
 
?
10

Considerations and recommendations for assessment of plasma..:

Humphreys, Sara C ; Davis, John A ; Iqbal, Sajida...
Nucleic Acids Research.  50 (2022)  11 - p. 6020-6037 , 2022
Link: https://doi.org/10.1093/..
 
?
11

Safety and efficacy of the cystic fibrosis transmembrane co..:

Kazani, Shamsah ; Rowlands, David J. ; Bottoli, Ivan...
Journal of Cystic Fibrosis.  20 (2021)  2 - p. 250-256 , 2021
Link: https://doi.org/10.1016/..
 
?
12

Efficacy and Safety of the CFTR Potentiator Icenticaftor (Q..:

Rowe, Steven M ; Jones, Ieuan ; Dransfield, Mark T...
International Journal of Chronic Obstructive Pulmonary Disease.  15 (2020)  - p. 2399-2409 , 2020
Link: https://doi.org/10.2147/..
 
?
13

Bioequivalence and food effect assessment for vildagliptin/..:

Mita, Sachiko ; Chitnis, Shripad D. ; Kulmatycki, Kenneth...
Int. Journal of Clinical Pharmacology and Therapeutics.  54 (2016)  4 - p. 305-314 , 2016
Link: https://doi.org/10.5414/..
 
?
14

Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 I..:

Meyers, Charles D. ; Noe, Adele ; Salunke, Atish...
Clinical Pharmacology in Drug Development.  5 (2016)  6 - p. 450-459 , 2016
Link: https://doi.org/10.1002/..
 
?
15

The DGAT1 inhibitor pradigastat does not induce photosensit..:

Bauer, Daniel ; Soon, Rachel L. ; Kulmatycki, Kenneth...
Photochemical & Photobiological Sciences.  15 (2016)  9 - p. 1155-1162 , 2016
Link: https://doi.org/10.1039/..
 
1-15